PTOISBI'DBa (03-15)
`Doc code: IDS
`Approved for use through 071312016. OMB 0651-0031
`.
`.
`.
`_
`.
`.
`us. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Doc description. Information Disclosure Statement (IDS) FIIed
`Under the Paperwork Reduction Act of 1995. no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`
`| 5789862
`
`
`
`
`I N
`
`
`
`IA
`
`
`
`
`IN FORMATION DISCLOSU RE
`
`Application Number
`Filing Date
`
`First Named Inventor
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`Art Unit
`
`
`
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`I AVN-OOQDVCNT
`
`
`
`
`
`U.S.PATENTS -
`
`Examiner Cite
`Initial*
`No
`
`Patent Number
`
`Kind
`Code1 Issue Date
`
`Name of Patentee or Applicant
`Of cited Document
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`
`
`If you wish to add additional US. Patent citation information please click the Add button. Add
`U.s.PATENT APPLICATION PUBLICATIONS -
`
`
`
`
`
`
`
`
`
`
`
`Examiner
`Initial*
`
`Publication
`one No Number
`
`Publication
`Kind
`Code1 Date
`
`Name of Patentee or Applicant
`Of cited Document
`
`
`
`Pages,Columns,Lines where
`Relevant Passages or Relevant
`Figures Appear
`
`
`If you wish to add additional U.S. Published Application citation information please click the Add button. Add
`FOREIGN PATENT DOCUMENTS -
`
`
`Examiner Cite Foreign Document
`Initial*
`No
`Number3
`
`
`Country
`Code2i
`
`Publication
`Kind
`Code4 Date
`
`
`
`1
`2
`3
`
`'000-325085 |. 2000—11—28
`'002-10790 |. 2002—01—15
`'002-325582 |. 2002—11—12
`
`Name of Patentee or
`A licant of cited
`pp
`Document
`
`atsuoMasafumi,etal.
`atsuoMasafumi
`atsuo,Masafumietal.
`
`EFS Web 2.1.17
`
`Pages,Columns,Lines
`where Relevant
`Passages or Relevant
`.
`
`FIgures Appear
`
`
`
`X
`E
`E
`
`
`
`

`

`
`
`IN FORMATION DISCLOSU RE
`
`
`First Named Inventor
`Peter SAZANI
`
`
`Application Number
`15789862
`
`
`Filing Date
`2017-10-20
`
` Attorney Docket Number
`
`
`Art Unit
`| MIA
`Examiner Name
`Not Yet Assigned
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`‘
`
`OOh"
`
`DCD01"*4
`
`:5oH"Lnm32coco
`
`0o1"Ln9toanMN
`
`:5 A ‘F’Ma:coon ‘ Ln
`
`20024127
`
`atsushita Electric Ind
`
`2002—09—10
`
`|i Lilly and Company
`
`2004—04—02
`
`- cademisch Ziekenhuis
`elden
`
`2010—12—02
`
`atsuo Masafumi
`
`‘
`
`O _| d l_‘ D _\ CDU1U1
`
`201 1—05—26
`
`- cademisch Ziekenhuis
`elden
`
`‘
`
`O _| d
`
`-200235
`
`2011—10—13
`
`- cademisch Ziekenhuis
`elden
`
`2014—03—27
`
`ippon Shinyaku Co Ltd,
`
`
`
`
`I AVN-OOQDVCNT
`
`
`
`
`
`vvvDOO_|_|_|'F''F''F'_\_\D _\g_‘5E01G)MCDDO01CDonD
`
`—l—l00N
`
`- cademisch, Ziekenhuis
`elden et al.
`
`- cademisch, Ziekenhuis
`elden
`
`2014—05—1 9
`
`2014—07—31
`
`U3M
`
`201 1—09—21
`
`co'4h'sl0')"slCD‘40')“-4Ln"*4
`
`U3M
`
`2011—12—28
`
`- cademisch Ziekenhuis
`eiden
`
`4:.
`
`EFS Web 2.1.1?
`
`

`

`
`
`IN FORMATION DISCLOSU RE
`
`
`First Named Inventor
`Peter SAZANI
`
`
`Application Number
`15789862
`
`
`Filing Date
`2017-10-20
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Art Unit
`| MIA
`Examiner Name
`Not Yet Assigned
`
` Attorney Docket Number
`
`
`- VI Biopharma, Inc.
`
`
`I\JI\JI\J_.
`---------..EEiisiS993aN—‘mm-P_\4:coLonoNto0::tU1g23noa:an(.71anatwonanMM0U14:.0onw4:.coonnoN0'!0'!ODdU1U!—l-.|o
`
`I AVN-OOQDVCNT eiden
`
`UI
`
`82
`
`201 3—02—06
`
`atsuo Masafumi
`
`82
`
`2013—10—04
`
`- cademisch Ziekenhuis
`eiden
`
`—l ‘4
`
`A1
`
`2000—03—23
`
`niversity College
`ondon
`
`A1
`
`2000—08—03
`
`- VI Biopharma, Inc.
`
`A1
`
`2000—12—28
`
`urdoch Childrens
`esearch Institute
`
`2001—07—12
`
`2001—10—04
`
`—|
`
`2001—11—08
`
`ybn'don, Inc
`
`|\J|\J4k00
`
`2001—11—08
`
`- VI Biopharma, Inc.
`
`2002—03—07
`
`‘ VI BIOPHARMA, INC.
`
`|\JUI
`
`>
`
`2002—03—28
`
`- cademisch Ziekenhuis
`
`EFS Web 2.1.17
`
`

`

`
`
`IN FORMATION DISCLOSU RE
`
`
`First Named Inventor
`Peter SAZANI
`
`
`Application Number
`15789862
`
`
`Filing Date
`2017-10-20
`
` Attorney Docket Number
`
`
`Art Unit
`| MIA
`Examiner Name
`Not Yet Assigned
`
`A_\
`
`2002—04—1 1
`
`urto, James
`
`2003—07—03
`
`A1
`
`2004—06—1 0
`
`2004—09—30
`
`- cademisch Ziekenhuis
`eiden
`
`2004—09—30
`
`- cademisch Ziekenhuis
`eiden
`
`2005—12—08
`
`- vi Biopharma, Inc
`
`‘05
`
`niversity of Western
`. ustralia
`
`2006—03—02
`
`enethon et al.
`
`2006—10—26
`
`- cademisch Ziekenhuis
`eiden
`
`2007—05—24
`
`he University of North
`arolina at Chapel Hill et
`
`2007—1 1—22
`
`'hiladelphia Health &
`ducation Corporation, D
`
`
`I AVN-OOQDVCNT
`
`A1“nun-fl-fl-fl- 2006—01
`
`vvvvvvv----ooooooouhuh(.0N"sl"sl0')O)O)(.71J:-g(D-.-.-.-.-.-.D0°01AdC)dC)C)dmwmwo(A)(IIdNDdIb(Ii00mo:onN—t0Lnfl4;'-l4;mm'HI
`'HI0I503CD0-‘—‘(DoN(.71‘4NNbU1b'-l(D
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`|\J|\J"-40')
`
`|\JCO
`
`00000000N00N—‘C:(.0
`
`004:.
`
`000'1
`
`000')
`
`EFS Web 2.1.1?
`
`

`

`
`
`IN FORMATION DISCLOSU RE
`
`
`First Named Inventor
`Peter SAZANI
`
`
`Application Number
`15789862
`
`
`Filing Date
`2017-10-20
`
` Attorney Docket Number
`
`
`Art Unit
`| MIA
`Examiner Name
`Not Yet Assigned
`
`A_\
`
`2007—1 1—29
`
`- cademisch Ziekenhuis
`eiden
`
`- vi Biopharma, Inc.
`
`- cademisch Ziekenhuis
`eiden et al.
`
`2008—03—27
`
`2009—04—30
`
`A1
`
`2009—08—20
`
`
`
`3--fl-fl-flfl- 2010—10—28
`
`vvvvvvvvvvvDOOOOOOOOOO_|_|_|_|_|_|C)C)C)C)C)OOOOOOCDCDCDon“'5'-.-.-.-.-.-._‘-.-.-.-.dddC)C)C)DJdC)C)d00NdU1U1b(D0U1DO00CD00U10CCDa,—|IR0"U1h(.0CDco00U1W(.0'HI-‘-‘—|0')(DOOonD(DNNOU1(.0(A)N—|0')(.0U1"slU1
`
`I AVN-OOQDVCNT
`
`2009—11—19
`
`A1
`
`201 0—04—29
`
`- vi Biopharma, Inc
`
`3
`
`2010—05—06
`
`' rosensa Technologies
`
`2010—05—06
`
`3
`
`2010—10—14
`
`- cademisch Ziekenhuis
`eiden et al.
`
`- ssociation Institut de
`
`yologie et al.
`
`' rosensa Technologies
`
`>
`
`2010—12—02
`
`niversita Degli Studi di
`oma "La Sapienza"
`
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`—|
`
`4:-000000(.0CO"-I
`4:-4:-4:-00NC
`4:-4:-4:-O')U14:
`
`4:.N
`
`EFS Web 2.1.1?
`
`

`

`
`
`
`
`Application Number 15789862
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art U .
`
`nit
`I N/A
`Examiner Name
`Not Yet Assigned
`
`I AVN-OOQDVCNT
`
` Attorney Docket Number
`2011—03—03
`
`
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`.
`.
`( Not for submissmn under 37 CFR 1.99)
`
`0101135417
`
`2010—12—02
`
`”iverfita Deg." Stuf,“ di
`oma La Sapienza
`
`010,150231
`
`2010_12_29
`
`niversita Degli Studi di
`errara
`
`' 011/024077
`
`
`
`
`
`.
`.
`Examiner Cite
`.
`.
`,,
`Initials
`No
`
`
`NON-PATENT LITERATURE DOCUMENTS
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item
`.
`.
`.
`.
`.
`(book, magazme, Journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),
`.
`.
`.
`publisher, City and/or country where published.
`
`T5
`
`1
`
`i ON PS1966 Mass Spectrometry Data, Pages 8, Exhibit Number 1154 filed in Interferences 106,007 and 106,008 on
`ebruary 16, 2015.
`
`
`
`
`
`2
`
`3
`
`i ON PS1966 UPLC Data, Pages 2, Exhibit Number 1165 filed in Interferences 106,007 and 106,008 on February 16,
`
`i ON PS1967 Mass Spectrometry Data, Pages 7, Exhibit Number 1155 filed in Interferences 106,007 and 106,008 on
`ebruary 16, 2015.
`
`
`
`4
`
`i ON PS1967 UPLC Data, Pages 2, Exhibit Number 1166 filed in Interferences 106,007 and 106,008 on February 16,
`
`
`
`
`
`
`
`5
`
`6
`
`i ON PS229 (h53AON1) HPLC Chromatograph Pages 2, Exhibit Number 1140 filed in lnterferences 106,007 and
`06,008 on February 16, 2015.
`
`i ON PS229 (h53AON1) HPLC Method Report, Pages 3, Exhibit Number 1139 filed in Interferences 106,007 and
`06,008 on February 16, 2015.
`
`
`
`EFS Web 2.1.17
`
`

`

`
`
`
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`.
`.
`( Not for submissmn under 37 CFR 1.99)
`
`Application Number 15789862
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art U .
`
`mt
`I N/A
`Examiner Name
`Not Yet Assigned
`
` Attorney Docket Number
`
`
`
`—l—l54(A)N
`
`I AVN-009DVCN7
`
`A ON P8229 (h53AON1) Mass Spectrometry Data, Pages 3, Exhibit Number 1142 filed in Interferences 106,007 and
`06,008 on February 16, 2015.
`
`A ON P8229 (h53AON1) Synthesis Laboratory Notebook Entry, Pages 1, Exhibit Number 1137 filed in Interferences
`06,007 and 106,008 on February 16, 2015.
`
`A ON P8229L (h53AON229L) Certificate of Analysis, Pages 1, Exhibit Number 1129 filed in Interferences 106,007 and
`06,008 on February 17, 2015.
`
`A ON P843 (h51AON1) Certificate of Analysis, Pages 1, Exhibit Number 1134 filed in Interferences 106,007 and
`06,008 on February 16, 2015.
`
`A ON P843 (h51AON1) HPLC Chromatogram, Pages 1, Exhibit Number 1131 filed in Interferences 106,007 and
`06,008 on February 17, 2015.
`
`A ON P843 (h51AON1) HPLC Method Report, Pages 4, Exhibit Number 1130 filed in Interferences 106,007 and
`06,008 on February 17, 2015.
`
`A ON P843 (h51AON1) Mass Spectrometry Data, Pages 3, Exhibit Number 1135 filed in Interferences 106,007 and
`06,008 on February 16, 2015.
`
`A ON P843 (h51AON1) UPLC—UV Data, Pages 2, Exhibit Number 1136 filed in Interferences 106,007 and 106,008 on
`ebruary 16, 2015.
`
`A ONs P81958, PS1959, P81960, P81961, P81962, P81963, P81964, PS1965, P81966, and P8196? HPLC Method
`eport, Pages 3, Exhibit Number 1143 filed in Interferences 106,007 and 106,008 on February 16, 2015.
`
`—l—l—lLn4;
`
`A pplicant—Initiated Interview Summary dated April 8, 2013 in US Application Serial No. 137094548, (University of
`estern Australia Exhibit 2144, filed April 3, 2015 in Interferences 106007, 106008, and 106013, pages 1—11).
`
`‘4
`
`A rechavala—Gomeza V, et al., "Immunohistological intensity measurements as a tool to assess sarcolemma—associated
`rotein expression," Neuropathol Appl Neurobiol 2010,36: 265-74.
`
`EFS Web 2.1.1?
`
`

`

`
`
`
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`.
`.
`( Not for submissmn under 37 CFR 1.99)
`
`Application Number 15789862
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art U .
`
`mt
`I N/A
`Examiner Name
`Not Yet Assigned
`
` Attorney Docket Number
`
`
`
`
`I AVN-OOQDVCNT .iology, Vol. 15(5):444—451 (2008) (Exhibit Number 1057 filed in interferences 106008, 106007 on November 18,
`
`A RECHAVALA—GOMEZA, V. et al., "Comparative Analysis of Antisense Oligonucleotide Sequences for Targeted
`kipping of Exon 51 During Dystrophin Pre-mRNA Splicing in Human Muscle," Human Gene Therapy, Vol. 18:798-81l
`
`A RORA, Vikram et al., "c—Myc Antisense Limits Rat Liver Regeneration and Indicates Role for c—Myc in Regulating
`ytochrome P-450 3A Activity," The Journal of Pharmacology and Experimental Therapeutics, Vol. 292(3):921—928
`2000)
`
`|\JO
`
`A setek Danmark AIS v. CMI USA, Inc., 2014 WL 5990699, N_D. Cal. 2014, 8 pages, (Academisch Ziekenhuis Leiden
`xhibit 1237, filed May 5, 2015 in Interference 106007 and 106008).
`
`—|
`
`A SVADI, Parisa et al., "Expression and functional analysis of recombinant scFv and diabody fragments with specificity
`or human RhD," Journal of Molecular Recognition, Vol. 15:321-330 (2002)
`
`A ustralian Application No. 2004903474, 36 pages, dated July 22, 2005 (Exhibit Number 1004 filed in interferences
`06008, 106007 on November 18, 2014)
`
`AVI BioPharma, |nc., "Exon 51 Sequence of Dystrophin," Document D19 as filed in Opposition of European Patent
`P1619249, filed June 23, 2009, 7 pages
`
`|\J|\J|\J|\J|\J
`
`|\J|\J"-l0')
`
`|\JCO
`
`EFS Web 2.1.1?
`
`A L's PCT/NL03700214 (the as—filed AZL PCT Application) Exhibit No. 1006, filed in Interference No. 106,007, 64
`ages, December 23, 2014
`
`A L's US. Patent Application No. 14/295,311 and claims, as—filed June 3, 2014 ("the '311 Application") (Exhibit
`umber 1077 filed in interferences 106008, 106007 on December 23, 2014)
`
`A ofeifa J, et al., "X—chromosome methylation in manifesting and healthy carriers of dystrophinopathies: concordance
`f activation ratios among first degree female relatives and skewed inactivation as cause of the affected phenotypes,"
`urn Genet 1995;96:167—176.
`
`: EAUCAGE, S.L_ et al., "Deoxynucleoside Phosphoramidites - A New Class of Key lntennediates for
`I eoxypolynucleotide Synthesis," Tetrahedron Letters, Vol. 22(20): 1 859-1862 (1981)
`
`: ELLARE, Priya et al., "A role for ubiquitin in the spliceosome assembly pathway," Nature Structural & Molecular
`
`

`

`
`
`
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
` Application Number
`
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`
`: ELLARE, Priya et al., "Ubiquitin binding by a variant Jab1IMPN domain in the essential pre-mRNA splicing factor
`rp8p," RNA, Vol. 12:292-302 (2006) (Exhibit Number 1056 filed in interferences 106008,106007 on November 18,
`
`: ENNETT, C. Frank et al., "RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a
`herapeutic Platform," Annu. Rev. Pharmacol. Toxicol., Vol. 50:259—293 (2010) (Exhibit Number 1025 filed in
`nterferences 106008, 106007 on November 18,2014)
`
`: ERGE, Stephen M. et al., "Pharmaceutical Salts," Journal of Pharmaceutical Sciences, Vol. 66(1):1-18 (1977)
`
`: estas et al., "Design and Application of Bispecific Splice Switching Oligonucleotides," Nuc. Acid Therap., Vol. 24, No.
`, pp. 13—24 (2014), Exhibit Number 1120 filed in interferences 106,007 and 106,008 on February 17, 2015.
`
`RAASCH, Dwaine A. el al., "Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA," Chemistry &
`iology, Vol. 8:1—7 (2001) (Exhibit Number 2009 filed in interferences 106008, 106013, 106007 on November 18, 2014
`
`RAASCH, Dwaine A. et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,"
`iochemistry, Vol. 41(14):4503-4510 (2002) (Exhibit Number 2006 filed in interferences 106008, 106013, 106007 on
`ovember 18, 2014)
`
`: REMMER—BOUT, Mattie et al., "Targeted Exon Skipping in Transgenic hDMD Mice: A Model for Direct Preclinical
`creening of Human-Specific Antisense Oligonucleotides," Molecular Therapy, Vol. 10(2):232—240 (2004) (Exhibit
`umber 2024 filed in interferences 106008, 106013, 106007 on November 18, 2014)
`
`: rooke MH, el al., "Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials
`ased on the natural history," Muscle Nerve. 1983;6:91—103.
`
`
`
`
`|AVN-009DVCN7
`
`00|\JO(D
`
`00 _.
`
`0000000000
`
`000003"-l
`
`00(D
`
`EFS Web 2.1.17
`
`: ROWN, Susan C. et al., "Dystrophic phenotype induced in vitro by antibody blockade of muscle alpha-dystroglycan—
`aminin interaction," Journal of Cell Science, Vol. 112:209—21 6 (1999)
`
`: ushby K, et al. "Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and
`harrnacological and psychosocial management," Lancet Neurol 2010;9:77—93.
`
`: ushby KM, et al., "The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy," |l. Correlation o
`henotype with genetic and protein abnormalities. J Neurol 1993;240: 105—112.
`
`

`

`
`
`
`15789862
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`
`( Not for submission under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art Unit
`|NIA
`
` Application Number
`
`Examiner Name
`Not Yet Assigned
`Attorney Docket Number
`
`: ushby KM, et al., "The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy," |. Natural
`istory. J Neurol 1993;240:98—104.
`
`ANONICO, A.E_ et al., "Expression of a CMV Promoter Drive Human alpha—1 Antitrypsin Gene in Cultured Lung
`ndothelial Cells and in the Lungs of Rabbits," Clinical Research, Vol. 39(2):219A (1991)
`
`IRAK, Sebahattin et al., "Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy
`-fter systemic phosphorodiamidate morpholino oligomer treatment: an open—label, phase 2, dose—escalation study,"
`ancet, Vol. 378(9791):595—605 (2011)
`
`laim Chart 11/233,495, Pages 57, Exhibit Number 1216 filed in Interferences 106,007 and 106,008 on February 17,
`
`laim Chart 13/550,210, Pages 45, Exhibit Number 1217 filed in Interferences 106,007 and 106,008 on February 17,
`
`laim Chart, US 7,807,816, 14 pages (Exhibit Number 1063 filed in interferences 106008, 106007 on November 18,
`
`4:.
`
`4:-4:-4:-N—‘O
`4:-4:-4:---.|o)(It4:00
`4:-4:-4:-(D03
`
`
`
`
`|AVN-009DVCN7
`
`laim Chart, US 7,960,541, 17 pages (Exhibit Number 1064 filed in interferences 106008, 106007 on November 18,
`
`laim Chart, US 8,455,636, 32 pages (Exhibit Number 1062 filed in interferences 106008, 106007 on November 18,
`
`laim Comparison Chart — Claims 11 and 29 in 13/550,210, Pages 1, Exhibit Number 1226 filed in Interferences
`06,007 and 106,008 on February 17,2015.
`
`laim Comparison Chart 13/550,210 vs 11/233,495, Pages 12, Exhibit Number 1218 filed in Interferences 106,007 an
`06,008 on February 17, 2015.
`
`(.71O
`
`laim Comparison Chart 13/550,210 vs 12/ 198,007, Pages 1, Exhibit Number 1219 filed in Interferences 106,007 and
`06,008 on February 17, 2015.
`
`EFS Web 2.1.17
`
`

`

`
`
`
`
`Application Number 15789862
`
` Attorney Docket Number
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`.
`.
`( Not for submissmn under 37 CFR 1.99)
`
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art U .
`mt
`I N/A
`
`Examiner Name
`Not Yet Assigned
`
`
`
`I AVN-OOQDVCNT If you wish to add additional non-patent literature document citation information please click the Add button
`
`EXAMINER SIGNATURE
`
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a
`citation if not in conformance and not considered.
`Include copy of this form with next communication to applicant.
`
`1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO
`Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.
`4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 5 Applicant is to place a check mark here if
`English language translation is attached.
`
`EFS Web 2.1.17
`
`

`

`
`
`Application Number 15789862
`
`Filing Date
`2017-10-20
`First Named Inventor
`Peter SAZANI
`
`Art U .
`
`mt
`I N/A
`Examiner Name
`Not Yet Assigned
`I AVN-009DVCN7
`
`IN FORMATION DISCLOSU RE
`STATEMENT BY APPLICANT
`.
`.
`( Not for submissmn under 37 CFR 1.99)
`
`
`
` Attorney Docket Number
`
`
`
`
`
`Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):
`
`CERTIFICATION STATEMENT
`
`That each item of information contained in the information disclosure statement was first cited in any communication
`from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
`information disclosure statement. See 37 CFR 1.97(e)(1).
`
`OR
`
`That no item of information contained in the information disclosure statement was cited in a communication from a
`
`foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification
`after making reasonable inquiry, no item of information contained in the information disclosure statement was known to
`any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure
`statement. See 37 CFR 1.97(e)(2).
`
`El
`
`See attached certification statement.
`
`The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
`
`A certification statement is not submitted herewith.
`
`SIGNATURE
`
`A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the
`form of the signature.
`
`This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the
`public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR
`1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed
`application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you
`require to complete this form andlor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S.
`Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND
`FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria,
`VA 22313-1450.
`
`EFS Web 2.1.17
`
`
` NamelPrint
`Signature
`2017—10—30
`
`
`
`

`

`Privacy Act Statement
`
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the
`attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised
`that:
`(1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited
`is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to
`process and/or examine your submission related to a patent application or patent.
`If you do not furnish the requested
`information, the U.S. Patent and Trademark Office may not be able to process andr'or examine your submission, which may
`result in termination of proceedings or abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1.
`
`The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act
`(5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the
`Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record 5.
`
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a
`court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement
`negotiations.
`
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance from the
`Member with respect to the subject matter of the record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for
`the information in order to perform a contract. Recipients of information shall be required to comply with the
`requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`
`A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
`may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
`to the Patent Cooperation Treaty.
`
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of
`National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
`
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or
`his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to
`recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and
`2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this
`purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make
`determinations about individuals.
`
`A record from this system of records may be disclosed, as a routine use, to the public after either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record
`may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in
`an application which became abandoned or in which the proceedings were terminated and which application is
`referenced by either a published application, an application open to public inspections or an issued patent.
`
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
`
`
`
`
`
`
`
`EFS Web 2.1.17
`
`